Polymorphisms Contribution to the Determination of Significant Risk of Specific Toxicities in Multiple Myeloma

Investor logo

Warning

This publication doesn't include Faculty of Arts. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

ALMÁŠI Martina ŠEVČÍKOVÁ Sabina ŠVÁCHOVÁ Hana SÁBLÍKOVÁ Barbora MÁJKOVÁ Petra HÁJEK Roman

Year of publication 2011
Type Article in Periodical
Magazine / Source Klinická onkologie
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords single nucleotide polymorphisms (SNPs); genotyping; real-time PCR; allelic discrimination; toxicity; multiple myeloma
Description The introduction of new drugs improved clinical response of patients with diagnosed multiple myeloma (MM); however, MM is still an incurable disease that leads to frequent relapses. Individual genetic variability can significantly affect therapeutic response, sensitivity and toxicity. Analysis of single nucleotide polymorphisms (SNPs) to study genetic changes is the genomic method that can obtain information for improving the effectiveness of treatment with minimum undesirable toxicity followed by individual treatments. The aim of this paper is to explain the possibility of detection and evaluation of polymorphisms associated with toxicity of treatment in patients with MM.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.